Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Epuris Sales in Mexico

<< Previous

Bullboard Posts

Next >>

Post by nozzpackon Nov 23, 2021 11:28am

213 Views

Post# 34157222

Epuris Sales in Mexico

The isotretinion markets in Canada and Mexico are broadly similar.

It seems to me that Ciphers Epuris sales in Mexico will be about the same as that in Canada.

In Canada, CPH receives just under $10 million US per year for Epuris sales.

So, a significant boost in cash inflows should accrue from this launch of Epurid in Mexico.

CPH also has the rights for Brazil.

I have no idea of that status....

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario